Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 1 to 25 of 344

Type: Guidance`Remove $Type: Guidance filter`
Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance and quality standards awaiting development
Title	Type
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]	Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]	Technology appraisal guidance
Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]	Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]	Technology appraisal guidance
Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [ID6694]	Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture [ID6276]	Technology appraisal guidance
Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]	Technology appraisal guidance
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]	Technology appraisal guidance
AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]	Technology appraisal guidance
Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]	Technology appraisal guidance
Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]	Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]	Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]	Technology appraisal guidance
Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [GID-TA12005]	Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]	Technology appraisal guidance
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance
Aprocitentan for treating resistant hypertension [ID6681]	Technology appraisal guidance
Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [GID-TA12033]	Technology appraisal guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6558]	Technology appraisal guidance
Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]	Technology appraisal guidance

Results per page

10
25
50
All